Limana da Silveira · Brain research bulletin 2021 · preclinical animal experiment · n=?

Caenorhabditis elegans as a model for studies on quinolinic acid-induced NMDAR-dependent glutamatergic disorders.

Cited 8 times in the scientific literature.

Level 5 - mechanism / opinion, no new human data

Preclinical animal model study (invertebrate / bench research)

PubMed 34271120 · doi:10.1016/j.brainresbull.2021.07.007 · record verified 2026-08-28

What was done

The authors investigated the behavioral and metabolic toxicity of quinolinic acid (QUIN), an NMDA receptor agonist, in wild-type and nmr-1/nmr-2 mutant Caenorhabditis elegans. They assessed locomotion parameters (wavelength, movement amplitude, speed, displacement, body bends), chemosensory response latency to 1-octanol, brood size, lifespan, and mitochondrial metrics including oxygen consumption, mitochondrial membrane potential, ATP-coupled electron flow, and citrate synthase activity.

What was found

The abstract reports no numerical values, effect estimates, or variance statistics. Reported directional effects include: - QUIN increased movement wavelength, amplitude, speed, and displacement in an NMDAR-dependent manner, with no effect on body bend count. - QUIN prolonged response latency to 1-octanol. - QUIN increased brood size in an nmr-2-dependent manner, without altering lifespan. - In wild-type worms, QUIN reduced oxygen consumption, mitochondrial membrane potential, and coupled/unbound electron flow to ATP production, without altering citrate synthase activity.

Why it matters

This study establishes C. elegans as an invertebrate model displaying NMDAR-dependent behavioral and mitochondrial deficits from quinolinic acid toxicity analogous to mammalian models.

Limits

The study was conducted entirely in an invertebrate model and provides no human clinical data. Sample sizes (n), quinolinic acid exposure concentrations, treatment durations, and quantitative effect sizes are not reported in the abstract.

Cited by